There was a problem loading this presentation. You may not have permission to view it.

You do not have permission to view this presentation.

Treatment of Metastatic Melanoma in 2019


An error occurred while loading this content.

Please refresh the page to try again.

Refresh Now
You previously started this content
Login or join to view
Click to Play

Treatment of Metastatic Melanoma in 2019

Lars Bastholt
Consultant Clinical Oncologist, Odense University Hospital, Odense, Denmark

As a leading expert in the field of metastatic melanoma, Lars Bastholt runs through the recent developments that have transformed treatment of this disease and vastly improved average prognosis. He covers the major trials of drugs targeting the activated MAPK pathway and those blocking CTLA4 and PD1. There is information on which toxicities to look out for with particular regimens, as well as useful guidance on selecting the most appropriate treatment according to patient factors such as disease aggressiveness and molecular biomarkers. Finally, Professor Bastholt looks to trials in progress and how treatment may change in the near future.